Introduction {#s1}
============

Induced pluripotent stem cells (iPSCs) can be generated from various cell types by the enforced expression of transcription factors such as OCT4, KLF4, SOX2 and MYC (OKSM) ([@bib51]). Reprogramming requires a complex coordination of cellular events to transition cells from a differentiated to a self-renewing fate. Many aspects of the molecular machinery governing pluripotency have been uncovered, with the focus on transcriptional regulation, and chromatin modifications. The master transcription factors OCT4, SOX2 and NANOG together with many other factors maintain pluripotency both in iPSCs and embryonic stem cells (ESCs) derived from the inner cell mass of the blastocyst stage embryo ([@bib13]). Chromatin modifiers, such as the polycomb repressive complex 1 and 2 (PRC1/2), control self-renewal and differentiation potential by repressing lineage-specific genes and they reset the epigenetic landscape during reprogramming ([@bib13]; [@bib51]).

RNA processing mediated by RNA-binding proteins (RBPs) encompasses many steps in the life of an RNA including pre-mRNA splicing, termination and polyadenylation, nonsense mediated decay (NMD) and mRNA export, with potential to significantly modify the gene expression output at each step. Global changes in alternative splicing (AS) and polyadenylation (APA) patterns take place during reprogramming ([@bib11]; [@bib25]; [@bib34]; [@bib44]) but the functional significance of the differential RNA processing is not well understood. Remarkably, ESCs express more than 500 different RBPs ([@bib33]), the RBPs investigated to date highlighting the potential of RNA regulation in the control of pluripotency. For instance, MBNL1/2 splicing factors act as negative regulators of pluripotency and reprogramming ([@bib15]), the ectopic expression of the splicing factor ESRP1 enhances reprogramming ([@bib11]) and SRSF2 regulates alternative splicing in human pluripotent stem cells ([@bib39]). FIP1 (encoded by *Fip1l1*) promotes maintenance of pluripotency by activating ESC-specific APA profiles ([@bib34]).

SRSF3 (serine-arginine-rich splicing factor 3) belongs to the family of SR protein splicing factors. We and others have previously shown that SRSF3 regulates constitutive and alternative splicing as well as other steps of RNA metabolism ([@bib5]; [@bib4]; [@bib9]; [@bib21]; [@bib41]; [@bib57]). At the cellular level, SRSF3 expression is regulated during cell cycle, SRSF3 overexpression in cancer cells enhances cell proliferation and its depletion leads to a cell cycle arrest ([@bib26]; [@bib27]; [@bib32]). SRSF3 plays a pivotal role during development as *Srsf3*-null mice fail to form blastocysts ([@bib28]). SRSF3 was also identified as a potential regulator of reprogramming in an RNAi screen performed in mouse embryonic fibroblasts (MEFs) ([@bib44]), but the molecular or cellular mechanisms mediated by SRSF3 during reprogramming are not known. Despite the global identification of SRSF3 RNA targets ([@bib3]; [@bib5]; [@bib41]), the functional significance of SRSF3 RNA-binding activity in vivo remains poorly characterised.

Here, we establish how SRSF3 governs pluripotency through its activities in RNA metabolism. Using individual-nucleotide resolution UV crosslinking and immunoprecipitation (iCLIP) and RNA sequencing (RNA-seq), we have identified a pluripotency circuitry directly regulated by SRSF3. We provide evidence for the critical role of SRSF3 in NANOG protein expression through its splicing-independent activity in the nucleo-cytoplasmic export of *Nanog* mRNA. However, SRSF3 function is not limited to regulating *Nanog*. To coordinate the pluripotency gene expression program, SRSF3 binds to multiple other (pre-)mRNAs encoding core pluripotency transcription factors, chromatin modifiers and RNA processing factors, including the export factor *Nxf1*. By combining SRSF3 RNA-binding sites with RNA-sequencing and functional data, we demonstrate that SRSF3 operates through multiple RNA processing mechanisms to tune and coordinate gene expression at the post-transcriptional level to establish and maintain pluripotency.

Results {#s2}
=======

SRSF3 facilitates reprogramming {#s2-1}
-------------------------------

To investigate the role of SRSF3 in reprogramming and self-renewal, we generated a reprogrammable tamoxifen inducible *Srsf3* knockout mouse model (*Srsf3*-KO/OKSM; [Figure 1A](#fig1){ref-type="fig"}). In cells isolated from these mice, reprogramming can be activated by Dox leading to reversible expression of OKSM factors, and Cre-recombinase can be induced by 4-hydroxy-tamoxifen (4OHT), resulting in the deletion of exons 2--3 of *Srsf3*. Cre-negative control MEFs reprogrammed with a high efficiency and gave rise to *bona fide* iPSCs capable of forming teratomas ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), consistent with our previous report ([@bib1]). During reprogramming, *Srsf3* mRNA expression was upregulated first at day 3, followed by a sharp increase by day 9 ([Figure 1B](#fig1){ref-type="fig"}, dotted line). Analysis of several independent cell lines revealed significantly higher levels of *Srsf3* mRNA in ESCs and iPSCs compared to MEFs ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). The biphasic increase in *Srsf3* expression coincided with the two transcriptional waves of reprogramming ([@bib45]), where during the first wave the cell proliferation increases, lineage-specific genes are downregulated and major metabolic changes take place and during the second wave genes required for stem cell maintenance are activated. RNA-sequencing data showed an increase in *Srsf3* mRNA expression specifically in cells that successfully formed iPSCs compared to cells refractory to reprogramming ([@bib45]) ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}).

![SRSF3 is essential for reprogramming.\
(**A**) The breeding strategy to obtain reprogrammable mice with a conditional *Srsf3* knockout allele (*Srsf3*-KO/OKSM). (**B**) Experimental outline of the reprogramming experiments (*top*). Quantification of *Srsf3* mRNA levels by RT-qPCR in SRSF3 depleted (KO) and control (Ctrl) cells in the course of reprogramming from day 1 to day 16 (*left*). Days 1--6 are shown on the right to visualise the expression changes within the first phase of reprogramming. Two-way ANOVA (\*\*\*p=0.0002 for genotype, \*\*\*p=0.0008 for time and \*p=0.0154 the interaction, data as mean ± SEM, n = 3--5). (**C**) Alkaline Phosphatase (AP) labelling of SRSF3 deficient (KO) and control (Ctrl) cells at day 16 of reprogramming (*left*) and quantification of AP-positive colonies (*right*). The data is presented as a relative number of colonies between treated (+4 OHT) and untreated (−4OHT) cells reprogrammed in parallel (Unpaired Student's t-test, two-tailed, \*\*p\<0.01, data as mean ± SEM, n = 4--5). (**D**) Quantification of *Pou5f1* mRNA expression by RT-qPCR during reprogramming in SRSF3 depleted (KO) and control (Ctrl) cells. The grey arrow denotes the point of Dox withdrawal and start of endogenous *Pou5f1* expression (data as mean ± SEM, n = 2). The data is normalised to *Hprt* and presented relative to control MEFs. (**E**) Experimental outline (*top*) of experiments where MEFs were reprogrammed for 8 days before SRSF3 depletion. Quantification of AP positive colonies (*left*) and pluripotency marker expression (*right*) at day 16 of reprogramming as in (**C**). The AP counts and mRNA expression are presented as above (Unpaired Student's t-test, two-tailed, \*\*p\<0.01, data as mean ± SEM, n = 4). (**F**) Experimental outline of the SRSF3 overexpression experiments (*top*). AP labelling of colonies at day 16 of reprogramming and quantification of AP-positive colonies. The data is presented relative to GFP-only (Ctrl) transfected cells (Unpaired Student's t-test, two-tailed, \*p\<0.05, data as mean ± SEM, n = 3). See also [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.](elife-37419-fig1){#fig1}

To determine how SRSF3 depletion affects reprogramming efficiency, *Srsf3*-KO/OKSM MEFs were first treated with 4OHT for 24 hr before inducing the OKSM transgene expression with Dox. The 4OHT exposure resulted in a sustained reduction of *Srsf3* mRNA ([Figure 1B](#fig1){ref-type="fig"}, solid line), with no effect on control cells. After removal of Dox at day 13, the cells were cultured for an additional 3 days to generate transgene independent iPSCs. The iPSC colonies were detected by alkaline phosphatase (AP) labelling both at day 13 (prior to Dox removal) and at day 16. The numbers of AP positive colonies were significantly reduced in SRSF3-depleted cells compared to controls and untreated (−4OHT) cells ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). The few AP-positive colonies that were generated from SRSF3-deficient MEFs consistently failed to form teratomas (n = 5, [Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). The failure of SRSF3-depleted cells to induce the pluripotency program was further confirmed by a strongly reduced expression of *Nanog* and endogenous *Pou5f1* (encoding OCT4) from day 13 onwards when Dox - and ectopic OKSM expression - was removed ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}). We did not detect significant increase in cell death in SRSF3-deficient MEFs during reprogramming ([Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}), similar to previous observations ([@bib44]). As the first phase of reprogramming involves the activation of cell proliferation ([@bib45]), we also assessed cell proliferation in SRSF3-deficient reprogramming cells. We detected a systematic reduction in the number of SRSF3-depleted cells when compared to controls, whereas SRSF3 overexpression led to an increase in cell numbers ([Figure 1---figure supplement 1H](#fig1s1){ref-type="fig"}).

To assess the role of SRSF3 in the activation of the pluripotency program during the second phase of reprogramming, we first reprogrammed the cells for 8 days after which SRSF3 depletion was induced and AP-positive colonies detected at day 16. SRSF3 was efficiently depleted following 4OHT treatment by day 9 ([Figure 1---figure supplement 1I](#fig1s1){ref-type="fig"}) and the number of transgene-independent AP positive colonies was significantly reduced at day 16, accompanied by a reduced expression of pluripotency markers ([Figure 1E](#fig1){ref-type="fig"}). These data demonstrate that SRSF3 is required to activate the pluripotency program during reprogramming.

Finally, we determined if SRSF3 overexpression could improve the reprogramming outcome. Reprogrammable MEFs were transduced with a vector encoding *Srsf3* and a GFP reporter or only GFP ([Figure 1F](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1J](#fig1s1){ref-type="fig"}). Twenty-four hours later, reprogramming was induced with Dox and transgene-independent iPSC colonies were detected by AP labelling at day 16. SRSF3 overexpression in MEFs resulted in a significantly greater number of AP-positive colonies compared to GFP only controls ([Figure 1F](#fig1){ref-type="fig"}). Flow cytometric analysis of cell surface marker expression at reprogramming days 6 and 16 further supported the enhanced reprogramming efficiency ([Figure 1---figure supplement 1K](#fig1s1){ref-type="fig"}). This analysis demonstrates that SRSF3 is not only essential for reprogramming but is also able to boost the generation of AP-positive colonies.

SRSF3 is essential for the maintenance pluripotency {#s2-2}
---------------------------------------------------

To further address the role of SRSF3 is pluripotent cells, we generated iPSCs from *Srsf3*-KO/OKSM MEFs without 4OHT exposure and cultured them for multiple passages before Cre activation ([Figure 2A](#fig2){ref-type="fig"}). Light microscopic inspection showed a rapid loss of iPSC colony morphology following SRSF3 depletion ([Figure 2B](#fig2){ref-type="fig"}). NANOG protein expression was strongly reduced in SRSF3-deficient iPSCs ([Figure 2C](#fig2){ref-type="fig"}), supporting the exit from pluripotency. Surprisingly, *Nanog* mRNA levels were little affected while the expression of other pluripotency genes such as *Pou5f1* (encoding OCT4), *Sox2*, *Klf4*, *Zfp42* (encoding REX1) and *Myc* was strongly reduced ([Figure 2D](#fig2){ref-type="fig"}). Similar to MEFs, SRSF3 depletion in iPSCs led to a reduction in cell numbers ([Figure 2E](#fig2){ref-type="fig"}). Whereas SRSF3-deficient MEFs showed no cell death, the level of AnnexinV/PI-negative cells was reduced in SRSF3-depleted iPSCs compared to controls, indicative of an increase in apoptosis ([Figure 2F](#fig2){ref-type="fig"}). To exclude that the loss of pluripotency in SRSF3-deficient cells was due to apoptosis, we treated SRSF3 depleted and control iPSCs with the caspase inhibitor QVD and assessed pluripotency ([Figure 2F](#fig2){ref-type="fig"}). Even in the absence of apoptosis, SRSF3 depletion led to a stark increase in the number of differentiating colonies and reduction in the expression of pluripotency markers ([Figure 2G--I](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1A--B](#fig2s1){ref-type="fig"}), demonstrating that SRSF3 directly contributed to the maintenance of pluripotency. In support of this and unlike SRSF1 and SRSF2 ([@bib36]; [@bib54]), SRSF3 depletion did not result in increased γH2Ax levels marking DNA double stranded breaks ([Figure 2H](#fig2){ref-type="fig"}), suggesting that SRSF3 loss does not lead to genomic instability. These data demonstrate an essential role for SRSF3 in self-renewing cells, loss of SRSF3 leading to exit from pluripotency independent of cell death.

![SRSF3 depletion leads to loss of pluripotency independent of cell death.\
(**A**) Experimental outline of the *Srsf3*-KO iPSC generation. (**B**) Phase contrast images of SRSF3 depleted (KO) and control (Ctrl) iPSCs 24 and 48 hr after 4OHT induction. Scale bar: 50 μm. (**C**) Western blot analysis of SRSF3 and NANOG expression in SRSF3 deficient (KO) and control (Ctrl) iPSCs 24 and 48 hr after 4OHT induction. ACTIN served as a loading control. (**D**) Quantification of *Srsf3* and pluripotency marker mRNA expression in *Srsf3*-KO (KO) and control (Ctrl) iPSCs 24 hr after 4OHT induction. The data is normalised to *Hprt* and presented relative to control iPSCs (Unpaired Student's t-test, two-tailed, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, data as mean ± SEM, n = 3). (**E**) Quantification of cell numbers 24 and 48 hr after 4OHT induction in *Srsf3*-KO (KO) and control (Ctrl) iPSCs (Unpaired Student's t-test, two-tailed, \*p\<0.05, data as mean ± SEM, n = 4). (**F**) Quantification of live cells in untreated and QVD treated *Srsf3*-KO (KO) and control (Ctrl) iPSCs by AnnexinV/PI labelling and flow cytometry 48 hr after 4OHT induction (Unpaired Student's t-test, two-tailed, \*p\<0.05, data as mean ± SEM, n = 3). (**G**) Quantification of pluripotent and differentiated iPSC colonies in untreated and QVD treated *Srsf3*-KO (KO) and control (Ctrl) iPSCs. Colonies were scored from three independent experiments. (**H**) Western blot analysis of γH2Ax and NANOG expression in QVD treated *Srsf3*-KO (KO) and control (Ctrl) iPSCs 48 hr after 4OHT induction. ACTIN served as a loading control. (**I**) Quantification of *Srsf3* and pluripotency marker mRNA expression in QVD treated *Srsf3*-KO (KO) and control (Ctrl) iPSCs 24 hr after 4OHT induction. The data is normalised to *Hprt* and presented relative to control iPSCs (data as mean ± SEM, n = 2). See also [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.](elife-37419-fig2){#fig2}

iCLIP reveals SRSF3 binding to RNAs encoding key factors of the pluripotency circuitry {#s2-3}
--------------------------------------------------------------------------------------

To determine if SRSF3 directly regulates the expression of pluripotency factors, we performed individual-nucleotide-resolution UV crosslinking and immunoprecipitation (iCLIP) ([Figure 3A](#fig3){ref-type="fig"}) ([@bib5]; [@bib22]). First, we generated ESCs expressing GFP-tagged SRSF3 at an endogenous level from a BAC transgene ([@bib3]). Nuclear GFP expressing ESCs served as controls ([Figure 3---figure supplement 1A--B](#fig3s1){ref-type="fig"}, [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}--[2](#fig3sdata2){ref-type="supplementary-material"}). In parallel, we also performed iCLIP using an antibody against the endogenous SRSF3. The pooled SRSF3-GFP iCLIP reads yielded 3.3M unique crosslink sites compared to 51K in the control while the anti-SRSR3 iCLIP resulted in low read coverage, suggesting a poor affinity of the antibody to RNA-bound SRSF3 ([Figure 3---source data 3](#fig3sdata3){ref-type="supplementary-material"}, [Figure 3---source data 4](#fig3sdata4){ref-type="supplementary-material"}). Significant crosslink sites were identified as previously described (FDR \< 0.05, ([@bib5]; [@bib31])), resulting in 219K SRSF3-GFP sites in the pluripotent transcriptome ([Figure 3---source data 4](#fig3sdata4){ref-type="supplementary-material"}). The consensus binding motif was consistent with previous SRSF3-GFP iCLIP and in vitro studies ([Figure 3B](#fig3){ref-type="fig"}) ([@bib5]; [@bib16]; [@bib41]). The consensus binding motifs of anti-SRSF3 and SRSF3-GFP iCLIPs were identical ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}) and there was a high overlap (74%) between anti-SRSF3 and SRSF3-GFP CLIP sites, consistent with previous studies demonstrating the functionality of SRSF3-GFP ([@bib3]). Because SRSF3-GFP resulted in \~100 fold higher number of unique cDNAs than the anti-SRSF3 iCLIP, we only proceeded with the analysis of SRSF3-GFP iCLIP data. SRSF3-binding sites were distributed over various RNA segments, including exons and introns both in coding and non-coding RNAs ([Figure 3C](#fig3){ref-type="fig"}). Gene Ontology (GO) analysis of genes with significant SRSF3 binding sites showed an enrichment in functions related to RNA metabolism ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}), supporting previous observations ([@bib5]; [@bib41]). Importantly, we detected an enrichment across GO terms associated with chromatin modifications, transcriptional regulation, cell division/cycle and DNA damage response ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}), which are central functions in the establishment and maintenance of pluripotent cells.

![SRSF3 binds to RNAs encoding key pluripotency factors.\
(**A**) Schematic of iCLIP to determine SRSF3 binding sites in pluripotent cells. (**B**) SRSF3 consensus binding motif in pluripotent cells. (**C**) Distribution of significant SRSF3 crosslink sites (FDR \< 0.05) over different transcript regions normalised to feature length. (**D**) SRSF3 binding sites detected in RNAs encoding key pluripotency regulators of multiple functional categories. (**E**) Functional association network of SRSF3 and its RNA targets in pluripotent cells. No connection between SRSF3 and the NANOG centred pluripotency network has been previously assigned. Pluripotency regulators that were directly bound by SRSF3 were used as input for STRING ([@bib50]). The pluripotency associated transcription factors and chromatin modifiers were based on [@bib55]) and mRNA processing factors based on [@bib10]). The thickness of the line reflects the confidence level for the interaction (highest 0.9 -- high 0.7 -- medium 0.4 -- low 0.15), large nodes represent proteins with some structural information. See also [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}--[4](#fig3sdata4){ref-type="supplementary-material"}.\
10.7554/eLife.37419.008Figure 3---source data 1.iCLIP peaks for SRSF3-EGFP.\
10.7554/eLife.37419.009Figure 3---source data 2.iCLIP peaks for EGFP-NLS.\
10.7554/eLife.37419.010Figure 3---source data 3.iCLIP peaks for anti-SRSF3.\
10.7554/eLife.37419.011Figure 3---source data 4.SRSF3 iCLIP mapping statistics.](elife-37419-fig3){#fig3}

Guided by the GO analysis, we next analysed SRSF3-binding sites within the pluripotency circuitry. SRSF3 bound to a large number of (pre-)mRNAs encoding pluripotency transcription factors ([Figure 3D](#fig3){ref-type="fig"}), including *Nanog, Pou5f1*, *Zfp42, Klf4, Sox2* and *Myc* that were downregulated in SRSF3 depleted iPSCs (see [Figure 2D](#fig2){ref-type="fig"}). Significant SRSF3-binding sites were also detected in RNAs encoding chromatin modifiers ([Figure 3D](#fig3){ref-type="fig"}) such as the components of PRC2 required to deposit repressive histone-3 lysine-27 tri-methyl (H3K27me3) marks in self-renewing cells. Interestingly, SRSF3 bound to RNAs encoding RBPs with previously assigned roles in reprogramming and/or pluripotent cells ([Figure 3D](#fig3){ref-type="fig"}). For example, MBNL1/2 splicing factors have been shown to act as negative regulators of pluripotency and reprogramming ([@bib15]) and FIP1 (encoded by *Fip1l1*) to promote the maintenance of pluripotency ([@bib34]). Functional protein association network analysis by STRING ([@bib50]) showed that the pluripotency related - as defined by ([@bib10]; [@bib55]) - SRSF3 RNA targets formed an interconnected network while SRSF3 has not been previously assigned as part of this network ([Figure 3E](#fig3){ref-type="fig"}), demonstrating that our iCLIP analysis determined hitherto uncharacterised regulatory interactions in pluripotent cells.

SRSF3 regulates NANOG protein levels by mediating the export of Nanog mRNA {#s2-4}
--------------------------------------------------------------------------

The genome wide-analysis suggested that SRSF3 directly controls a NANOG-centred pluripotency network. To determine the molecular mechanism underlying SRSF3 function in pluripotency, we first turned our attention to NANOG, the core transcriptional regulator in pluripotent stem cells. We wondered why NANOG protein expression was drastically reduced, whereas *Nanog* mRNA expression was largely unaffected in SRSF3 deficient iPSCs ([Figure 2C--D](#fig2){ref-type="fig"}). Although *Nanog* gene produces three annotated splice variants, only one of the variants was significantly expressed in iPSCs based on our RNA-seq data ([Figure 4A](#fig4){ref-type="fig"}). This variant encodes the full-length (FL) NANOG protein, whereas the two other splice variants produce an N-terminally truncated (TR) isoform. RT-qPCR analysis showed that SRSF3 depletion did not affect the first exon choice of *Nanog* mRNA ([Figure 4B](#fig4){ref-type="fig"}). A previous study in P19 cells predicted *Nanog* as one of \~400 mRNAs whose nucleo-cytoplasmic export was affected by SRSF3 knockdown ([@bib41]). The direct interaction of SRSF3 with the nuclear export factor NXF1 is well-documented ([@bib20]; [@bib21]; [@bib41]). Accordingly, subcellular fractionation revealed nuclear accumulation of *Nanog* mRNA in SRSF3 depleted iPSCs ([Figure 4C](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A--C](#fig4s1){ref-type="fig"}).

![SRSF3 binding and mRNA export adaptor activity in independent of splicing and essential for *Nanog* mRNA export.\
(**A**) *Nanog* expression and SRSF3 iCLIP binding profile within *Nanog* transcript region. Gene diagram depicting *Nanog* variants is presented below the graphs (FL = full length, TR = truncated). (**B**) *Left:* RT-qPCR quantification of *Srsf3* and *Nanog* mRNA expression in *Srsf3*-KO (KO) and control (Ctrl) iPSCs 24 hr after 4OHT induction. The data is normalised to *Hprt* and presented relative to control iPSCs (\*\*\*p\<0.001, Unpaired Student's t-test, two-tailed, data as mean ± SEM, n = 3). *Right:* Quantification of FL *Nanog* transcript levels relative to total *Nanog* mRNA levels (p\>0.05, Unpaired Student's t-test, two-tailed, data as mean ± SEM, n = 3). (**C**) *Srsf3*-KO (KO) and control (Ctrl) iPSCs were fractionated into nuclear, cytoplasmic and total fractions 24 hr after 4OHT induction (*left*). Quantification of *Nanog* mRNA levels in the nuclear and cytoplasmic fractions (*right*). Data is presented as nuclear to cytoplasmic ratio (\*p\<0.05, Unpaired Student's t-test, two-tailed, data as mean ± SEM, n = 5) and normalised to control. \#error bar smaller than the border line. (**D**) Generation of WT-*Nanog* and ΔSRSF3-*Nanog* expression constructs. Both constructs contain the complete *Nanog* cDNA, including 5' and 3' UTRs. In ΔSRSF3-*Nanog*, synonymous mutations have been introduced to remove SRSF3 binding sites (positions within the transcript denoted by red asterisks in the gene diagram). SRSF3 crosslink nucleotides are shown in red, SRSF3 consensus sequences are highlighted in yellow, and the underlined nucleotides were mutated to abolish SRSF3 consensus binding sites without affecting the coding potential. (**E**) RNA immunoprecipitation (IP) of WT- and ΔSRSF3-*Nanog* mRNA in SRSF3-GFP or GFP-only expressing pluripotent cells. The *Nanog* mRNA enrichment is presented as IP/input and normalised to GFP-only control cells expressing WT-*Nanog* (mean ± SEM, n = 2). (**F**) *Srsf3*-KO (KO) and control (Ctrl) iPSCs expressing WT-*Nanog* or ΔSRSF3-*Nanog* were fractionated into nuclear, cytoplasmic and total fractions 24 hr after 4OHT. Quantification of WT-*Nanog* and ΔSRSF3-*Nanog* mRNA levels in the nuclear and cytoplasmic fractions is presented as nuclear to cytoplasmic ratio and normalised to the control cells expressing WT-*Nanog* (\*p\<0.05, One-way ANOVA, data as mean ± SEM, n = 3). (**G**) RNA immunoprecipitation of WT- and ΔSRSF3-*Nanog* mRNA in SRSF3-GFP or GFP-only expressing HEK293 cells. Anti-NXF1 and anti-GFP antibodies were used to enrich mRNAs bound by NXF1 and SRSF3-GFP, respectively. The *Nanog* mRNA enrichment is presented as IP/input and normalised to GFP-only cells expressing WT-*Nanog* (mean ± SEM, n = 2). See also [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.](elife-37419-fig4){#fig4}

The subcellular fractionation analysis together with the robust reduction in NANOG protein levels following SRSF3 depletion in iPSCs (see [Figure 2C](#fig2){ref-type="fig"}) suggested that SRSF3 regulates NANOG protein levels through its mRNA export adaptor activity. To investigate mechanistically if direct SRSF3 binding to *Nanog* mRNA was required for its export, we generated *Nanog* expression constructs carrying either the wild type *Nanog* cDNA sequence including 3'UTR (hereafter WT-*Nanog*) or a *Nanog* cDNA sequence where silent mutations abolishing SRSF3-binding sites had been introduced (ΔSRSF3-*Nanog*) ([Figure 4D](#fig4){ref-type="fig"}). Following transfection into pluripotent cells, these constructs were expressed at similar levels, which did not exceed the endogenous levels ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). As expected, RNA immunoprecipitation showed strongly reduced binding of SRSF3 to ΔSRSF3-*Nanog* mRNA ([Figure 4E](#fig4){ref-type="fig"}). Nucleo-cytoplasmic fractionation demonstrated that ΔSRSF3-*Nanog* mRNA lacking SRSF3-binding sites was retained in the nucleus both in control and SRSF3-deficient cells ([Figure 4F](#fig4){ref-type="fig"}, dotted bars). The intronless mRNA produced from the WT-*Nanog* construct was efficiently exported in control cells while it was retained in the nucleus in SRSF3-depleted iPSCs ([Figure 4F](#fig4){ref-type="fig"}, compare white and black bars). This demonstrates firstly, that SRSF3 binding is essential for *Nanog* mRNA export and secondly, that SRSF3 activity in *Nanog* mRNA export is independent of pre-mRNA splicing. We also transfected the WT-*Nanog* or ΔSRSF3-*Nanog* expression construct into HEK293 cells that do not express endogenous *Nanog* and do not functionally depend on NANOG protein. Similar to pluripotent cells, SRSF3 bound to WT-*Nanog* but not ΔSRSF3-*Nanog* mRNA ([Figure 4G](#fig4){ref-type="fig"}, right αGFP IP). RNA immunoprecipitation with an anti-NXF1 antibody showed NXF1 binding to WT-*Nanog* mRNA while in the absence SRSF3-binding sites the *Nanog*-NXF1 interaction was abolished ([Figure 4G](#fig4){ref-type="fig"}, left αNXF1 IP; [Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}), demonstrating that SRSF3 binding is required for the association of NXF1 with *Nanog* mRNA. This is to our knowledge one of the first direct demonstrations of the functional importance of SRSF3 as an mRNA export adaptor as well as of the significance of RNA processing in the control of *Nanog* expression.

SRSF3 regulated alternative splicing in pluripotent cells and during reprogramming {#s2-5}
----------------------------------------------------------------------------------

Given that SR proteins are well-established regulators of pre-RNA splicing ([@bib6]; [@bib57]), we next performed RNA-sequencing of control and SRSF3-deficient iPSCs to investigate how SRSF3 impacts AS. We quantified the levels of alternatively spliced isoforms with MISO (Mixture-of-Isoforms) probabilistic framework ([@bib29]) using the annotated AS events for mouse GRCm38/mm10. Each AS event was assigned a 'percent spliced in' (PSI) or 'percent intron retained' (PIR) value to represent the percent of transcripts with the exon or intron included. Using a cut-off of ΔPSI≥\|0.2\| and Bayes factor ≥5, SRSF3 depletion led to a change in 281 annotated AS events, of which the skipped exon (SE) was the most affected category, both in terms of absolute numbers and proportion of assessed events ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). Overall, more exons showed increase in skipping following SRSF3 depletion, in agreement with the role of many SR proteins in enhancing exon inclusion. Sixty-one percent of the altered AS events had associated SRSF3-binding sites within the transcript region based on our iCLIP data. Because skipped exons were the most affected AS type in the SRSF3 deficient cells providing a sufficient number of data points for global analysis, we next mapped SRSF3-bindings sites around these exons. SRSF3 binding was enriched within the regulated exons, with few sites also mapping up- and downstream ([Figure 5B](#fig5){ref-type="fig"}). Inspection of SRSF3-binding sites around exons decreasing in inclusion in SRSF3 depleted cells suggested that SRSF3 binding within the regulated exon or intron enhances inclusion across the AS types (SE, IR, A5SS and A3SS) which is in accordance with SRSF3-binding sites acting as splicing enhancers ([Figure 5C](#fig5){ref-type="fig"}).

![SRSF3 regulated alternative splicing in pluripotent cells and the dynamics of AS during reprogramming.\
(**A**) Different alternative splicing (AS) types affected by SRSF3 depletion in pluripotent cells. Pluripotent cells were subjected to RNA sequencing 24 hr following SRSF3 depletion and AS changes were quantified by MISO (ΔPSI ≥ \|0.2\| and Bayes factor ≥5). SE, skipped exon; IR, intron retention; MXE, mutually exclusive exon; A3SS, alternative 3' slice site; A5SS, alternative 5' splice site. (**B**) SRSF3 binding sites (iCLIP) at and around SE events that were annotated by MISO. The red dots represent AS events that were considered significantly changed following SRSF3 depletion (Bayes factor \>5) and grey dots events that did not change (Bayes factor \<5). The opacity of the dots corresponds to the log~2~(iCLIP count) in the range 1 to 5 before log transformation. Significant SRSF3-binding sites with iCLIP count ≥2 that were not detected in the control iCLIP are shown. The dotted lines at 0 denote the 3' and 5' splice sites. (**C**) Representative examples of different AS types affected by SRSF3 depletion. SRSF3-binding sites mapping at and around the affected event are shown over the gene diagram (PSI values based on MISO, data as mean ± SEM, n = 2). PSI, percent spliced in; PIR, percent intron retained. Ctrl, control cells; KO, SRSF3-depleted cells. (**D**) Dynamic AS changes take place during reprogramming (MISO, ΔPSI ≥ \|0.2\| and Bayes factor ≥5). Comparison of each time point to MEFs showing a cumulative increase in AS from MEFs to iPSC (*top*) and assessment of consecutive time points demonstrating that the majority of AS changes take place in only two time points (*below*). (**E**) Different AS types display distinct dynamics during reprogramming. Cumulative and sequential change as in D, event types as in A. See also [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}--[3](#fig5sdata3){ref-type="supplementary-material"}.\
10.7554/eLife.37419.016Figure 5---source data 1.Alternative splicing events following SRSF3 depletion.\
10.7554/eLife.37419.017Figure 5---source data 2.Alternative splicing events during reprogramming relative to MEFs.\
10.7554/eLife.37419.018Figure 5---source data 3.Alternative splicing events between consecutive time points during reprogramming.](elife-37419-fig5){#fig5}

As regulated splicing plays a central role during reprogramming ([@bib11]; [@bib44]), we next assessed AS changes taking place in the course of reprogramming by performing RNA sequencing of control MEFs, reprogramming intermediates and iPSCs. We first determined cumulative changes in AS during reprogramming using MISO by comparing each of the time points to MEFs, which showed a gradual increase in AS from MEFs to iPSCs ([Figure 5D](#fig5){ref-type="fig"}, top panel) similar to previous reports ([@bib11]). Sequential comparisons between the time points revealed, however, that AS changes during reprogramming took place in two waves similar to transcriptional changes ([@bib45]). The apparent increase in AS towards iPSCs reflected major AS pattern alterations early between MEFs and day 3, and late between day 12 and iPSC ([Figure 5D](#fig5){ref-type="fig"}, bottom panel). When analysing the different types of AS events in the course of reprogramming, skipped exons were the major type across the time course although all AS types, including intron retention, were dynamically regulated during reprogramming ([Figure 5E](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}, [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"} and [3](#fig5sdata3){ref-type="supplementary-material"}).

Because MISO only assesses a limited set of previously annotated AS events, we also analysed regulated RNA processing during reprogramming using JunctionSeq which has been reported to readily detect novel splice junctions and intron retention ([Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}--[2](#fig6sdata2){ref-type="supplementary-material"}) ([@bib18]). Principal component analysis showed a molecular connectivity reflecting the progression from MEFs to iPSCs ([Figure 6A](#fig6){ref-type="fig"}), reminiscent but independent of the connectivity at the transcriptome level ([Figure 6---figure supplement 1A--B](#fig6s1){ref-type="fig"}) ([@bib45]). Similar to the analysis of annotated AS events using MISO, the number of regulated RNA features identified by JunctionSeq increased from MEFs to iPSC when each of the reprogramming intermediates was compared to MEFs ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). Sequential comparisons between each consecutive time point further demonstrated that the majority of RNA processing changes occurred at only two time points ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}), coinciding with the biphasic increase in *Srsf3* expression (see [Figure 1B](#fig1){ref-type="fig"}). We next mapped SRSF3-binding sites within and adjacent to the regulated RNA features identified by JunctionSeq (−200, +200 nt of the junction) to identify 'SRSF3 associated regulated RNA features' or 'SARFs'. Unsupervised k-means clustering grouped 53% of SARFs within 3 out of 20 clusters, each showing a similar upwards trajectory towards iPSCs ([Figure 6B](#fig6){ref-type="fig"}). As these three clusters represented only 33% of all regulated RNA features, we did not just detect the most prominent clusters but likely captured SRSF3 associated AS events relevant to the pluripotent cell fate. This examination shows that SRSF3 binding is associated with splicing changes contributing to the commitment to the pluripotent cell fate during reprogramming.

![SRSF3 regulates the alternative splicing of *Nxf1* and other RNA regulators during reprogramming.\
(**A**) Principal component analysis of regulated RNA features based on JunctionSeq during reprogramming, depicting similarity of exon/junction usage between reprogramming intermediates. (**B**) Unsupervised k-means clustering of regulated RNA features during the reprogramming time course. SRSF3 associated regulated RNA features, SARFs, are highlighted in red. SRSF3 binding sites within the feature or \[−200, +200 nt\] window up- or down-stream of the junction were included in the analysis. Top three clusters with most SRSF3-binding sites are shown. (**C**) (i) Distribution of SRSF3-binding sites within regulated exons and introns. Regulated RNA features were classified as exons and introns using RefSeq annotation. (ii) Proportion of intronic SARFs that were classified as detained introns ([@bib8]). (iii) Distribution of SRSF3 binding sites within regulated and non-regulated (non-reg.) DIs. (iv) Proportion of SARFs that are DIs and flank an exon regulated during reprogramming. (**D**) Expression of *Nxf1* Ex10-Int10-Ex11 during reprogramming and SRSF3 iCLIP binding profile within the transcript region. The red bars below the gene diagram denote DIs based on ([@bib8]). Colour coding from blue (MEF) to red (iPSC). The read counts were normalised within the genes. (**E**) Dynamic changes in *Nxf1*-Int10 retention during reprogramming as measured by RNA-seq (data as mean ± SEM, n = 2). PIR, percent intron retained. (**F**) RT-qPCR quantification of *Nxf1*-Int10 retention during reprogramming in control (Ctrl) and SRSF3-depleted (KO) cells. The data is represented as percent of transcripts with the retained intron (data as mean ± SEM, n = 2). (**G**) Expression of *Mbnl2* exons 5--8 and SRSF3 iCLIP binding profile within the transcript region. The red bars below the gene diagram denote DIs based on ([@bib8]). The alternative exon six is highlighted in black in the gene diagram. Colour coding from blue (MEF) to red (iPSC). The read counts were normalised within the genes. (**H**) Expression of *Fip1l1* exons 12--14 and SRSF3 iCLIP binding profile within the transcript region. The red bars below the gene diagram denote DIs based on ([@bib8]). The alternative exon 13 is highlighted in black in the gene diagram. (**I**) Dynamic changes in *Mbnl2*-Ex6 and *Fip1l*-Ex13 inclusion during reprogramming as measured by RNA-seq (data as ± SEM, n = 2). PSI, precent spliced in. (**J**) Quantification of *Mbnl2*-Ex6 and *Fip1l*-Ex13 inclusion in control (Ctrl) and *Srsf3*-KO (KO) iPSCs by RNA-seq (data as mean ± SEM, n = 2). Unaffected alternative exons that were not associated with SRSF3 binding sites (*Mbnl2*- Ex8 and *Fip1l1*-Ex9) are shown for comparison. PSI, percent spliced in. See also [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"} and [2](#fig6sdata2){ref-type="supplementary-material"}.\
10.7554/eLife.37419.021Figure 6---source data 1.Read-wide mapping statistics.\
10.7554/eLife.37419.022Figure 6---source data 2.Data file containing JunctionSeq output.](elife-37419-fig6){#fig6}

Examination of the SARFs during reprogramming revealed surprisingly abundant SRSF3 binding within intronic sequences ([Figure 6C,i](#fig6){ref-type="fig"}). A more detailed inspection detected a significant proportion of intronic SRSF3-binding sites mapping around so-called detained introns (DIs) ([Figure 6C,ii,iii](#fig6){ref-type="fig"}). DIs are defined as introns spliced out at a slower rate than an average intron, thus representing a rate-limiting regulatory step during splicing ([@bib8]). Only a small fraction of DIs were annotated as IR events and assessed by MISO but mapping of DIs to our JunctionSeq data identified differential DI inclusion from MEFs to iPSCs, with an increase in DI inclusion towards iPSCs ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). SRSF3-binding sites were found in 37% of regulated DIs in contrast to only 27% of non-regulated DIs ([Figure 6C,iii](#fig6){ref-type="fig"}). Similar to SRSF3 target RNAs (see [Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}), DI enrichment was reported in genes encoding proteins involved in RNA metabolism ([@bib8]). Indeed, SRSF3-binding sites were detected within DI regions of RNA regulators such as *Nxf1* pre-mRNA ([Figure 6D](#fig6){ref-type="fig"}). SRSF3-binding sites mapped to *Nxf1* intron 10, which was classified as DI and dynamically regulated during reprogramming ([Figure 6D--E](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}). Although the level of intron containing *Nxf1* mRNA was similar in MEFs and iPSCs, up to 40% intron retention was detected in the reprogramming intermediates ([Figure 6E](#fig6){ref-type="fig"}). SRSF3 ablation led to a decrease in the level of intron 10 containing *Nxf1* mRNA ([Figure 6F](#fig6){ref-type="fig"}), suggesting that SRSF3 binding is required for the dynamic changes in *Nxf1*-Int10 retention during reprogramming. The intron 10 containing *Nxf1* transcript encodes a short isoform of NXF1 protein that can bind to RNA but cannot interact with the nuclear pore complex ([@bib37]). NXF1 has been shown to bind to this intron to allow for the efficient export of the intron containing mRNA ([@bib38]; [@bib41]). Therefore, SRSF3 does not only act as an export adaptor of distinct mRNAs as exemplified by *Nanog* mRNA in pluripotent cells but also it may affect mRNA export more broadly by regulating NXF1 isoform expression and function through *Nxf1* intron 10.

In addition to *Nxf1*, we identified multiple other factors involved in RNA metabolism, including *Mbnl2, Fip1l1*, *Clk1* and *Ewsr1* that had SARFs in RNA regions with a DI ([Figure 6G--H](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1F](#fig6s1){ref-type="fig"}). Interestingly, MBNL2 and FIP1 have previously been shown to play regulatory roles in pluripotency ([@bib15]; [@bib34]) and CLK1 mediates dynamic changes in intron detention in ESCs ([@bib8]). Further assessment of these and other SARFs that were DIs showed a quarter of them flanking alternative exons that were regulated during reprogramming ([Figure 6D, iv](#fig6){ref-type="fig"}). The inclusion of the AS exons flanking DIs was dynamically regulated during reprogramming ([Figure 6I](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1G](#fig6s1){ref-type="fig"}) and SRSF3 ablation led to changes in their inclusion ([Figure 6J](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1H](#fig6s1){ref-type="fig"}). Of note, the alternative exon in *Srsf3* itself is flanked by DIs and we and others have previously shown that SRSF3 autoregulates the splicing of this exon ([@bib5]; [@bib35]; [@bib43]). These data show that the splicing of DIs provide a regulatory step in gene expression during reprogramming and demonstrates a role for SRSF3 in splicing of rate limiting DIs in pluripotent cells.

SRSF3 regulates the expression of chromatin modifiers essential for the repression of lineage-specific genes {#s2-6}
------------------------------------------------------------------------------------------------------------

SRSF3 does not only regulate splicing but also global gene expression ([@bib3]). In pluripotent cells, we identified 803 differentially expressed genes (DEGs) following SRSF3 depletion (482 up- and 321 downregulated, FDR \< 0.05, log\|FC\| ≥ 1) ([Figure 7A](#fig7){ref-type="fig"} and [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}). The GO terms associated with the dysregulated genes reflected the loss of pluripotency following SRSF3 depletion ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). Forty-four percent of DEGs had SRSF3 binding sites within transcript region (351 of 802), with no difference between genes that were up- (43%) or downregulated (45%). SRSF3 has been reported to regulate gene expression including its own mRNA abundance via NMD surveillance pathway ([@bib5]; [@bib35]; [@bib43]). We compared the SRSF3 CLIP RNA targets to previously identified transcripts regulated by NMD in mouse ESCs ([@bib23]). This revealed that almost half of the NMD-regulated genes/mRNAs had SRSF3-binding sites, suggesting that SRSF3-mediated RNA regulation may be broadly linked to NMD ([Figure 7B](#fig7){ref-type="fig"}). Further analysis demonstrated that DEGs with SRSF3-binding sites were enriched in the set of genes/mRNAs regulated by NMD ([Figure 7C](#fig7){ref-type="fig"}). The larger overlap within mRNAs \[or 'consistent isoforms' in [@bib23]) rather than genes suggested that SRSF3 may link distinct transcript variants to NMD.

![SRSF3 mediates the abundance of distinct mRNAs encoding chromatin modifiers to facilitate pluripotency.\
(**A**) Volcano plot depicting differentially expressed genes following SRSF3 depletion in pluripotent cells. The dotted lines illustrate fold change (FC) \>2 and FDR \< 0.05. (**B**) Number of genes and mRNAs regulated at the level of NMD based on [@bib23]) and the fraction of them with significant SRSF3 crosslink sites. (**C**) *Left*: Differentially expressed genes (DEGs) following SRSF3 depletion with and without SRSF3-binding sites. *Right*: The fraction of differentially expressed genes/mRNAs with (blue bars) and without (grey bars) SRSF3-binding sites that were regulated at the level of NMD. The percent value above the bars denotes the fraction of NMD regulated genes or mRNAs (dark blue or grey) in each category. (**D**) RT-qPCR quantification of PRC2 components in *Srsf3*-KO (KO) and control (Ctrl) iPSCs 24 hr after 4OHT induction. The data is normalised to *Hprt* and presented relative to control iPSCs (\*p\<0.05, Unpaired Student's t-test, two-tailed, data as mean ± SEM, n = 3--9). (**E**) Western blot analysis of H3K27me3 and total H3 levels 48 hr after 4OHT induction in *Srsf3*-KO (KO) and control (Ctrl) iPSCs. Quantification presented as H3K27me3 relative to total H3 (\*p\<0.05, Unpaired Student's t-test, two-tailed, data as mean ± SEM, n = 2). (**F**) *Top: Ezh2* expression in iPSCs and SRSF3 iCLIP binding profiles within the transcript region. Primers binding to the exons in red were used to measure the NMD-regulated transcript variant. *Below:* RT-qPCR quantification of total *Ezh2* (Ex2-3) and full-length transcript variant (Ex19-20) in control (Ctrl) and *Srsf3*-KO (KO) iPSCs before (-CHX) and after (+CHX) NMD inhibition. The data is normalised to *Hprt* and presented relative to control iPSCs (\*p\<0.05, One-way ANOVA, data as mean ± SEM, n = 3). (**G**) *Top: Dnmt3a* expression in iPSCs and SRSF3 iCLIP binding profiles within the transcript region. Primers detecting the alternative first exon (red) were used to measure the NMD-regulated transcript variant. *Below:* RT-qPCR quantification of total *Dnmt3a* (Ex22-23) and *Dnmt3a* alternative exon 1 (AltEx1) containing transcripts as in (**F**). See also [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.37419.025Figure 7---source data 1.Differentially expressed genes following SRSF3 depletion.](elife-37419-fig7){#fig7}

SRSF3 RNA targets were enriched in genes encoding chromatin modifiers including components of the PRC2 complex that in pluripotent cells deposits repressive H3K27me3 histone marks to suppress differentiation ([@bib56]) and *Dnmt3a* that encodes DNA methyl transferase 3A mediating gene silencing through the transfer of methyl groups to CpG islands ([Figure 3D](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). Interestingly, many of these mRNAs were also identified as NMD targets and have been shown to have short half-lives in pluripotent cells ([@bib23]; [@bib30]). The expression of multiple components of PRC2 was altered in SRSF3-deficient cells ([Figure 7D](#fig7){ref-type="fig"}) and consistent with this, the H3K27me3 levels were globally reduced ([Figure 7E](#fig7){ref-type="fig"}). *Ezh2* encoding the histone-lysine methyltransferase of PRC2 was among the NMD-sensitive SRSF3-bound mRNAs. Based on Ensembl gene annotation and previous studies ([@bib48]), *Ezh2* produces at least three transcript variants, one of which terminates at exon 7. Only the full-length (Ex1-20) variant was prominently expressed in pluripotent cells and SRSF3 binding sites were deposited along this mRNA ([Figure 7F](#fig7){ref-type="fig"}). To investigate the involvement of SRSF3 and NMD in the control of *Ezh2* expression, we measured *Ezh2* transcript variant mRNA levels in iPSCs treated with CHX. *Srsf3* mRNA, a known NMD target, served as a control for successful NMD inhibition ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). The total level of *Ezh2* determined by primers spanning exons 2--3 (Ex2-3) was not affected by NMD inhibition, whereas the level of the full-length *Ezh2* measured by primers spanning Ex19-20 was increased ([Figure 7F](#fig7){ref-type="fig"}). Intriguingly, the full-length *Ezh2* mRNA was downregulated in *Srsf3*-KO iPSCs ([Figure 7F](#fig7){ref-type="fig"}), providing evidence that SRSF3 specifically regulates the NMD-sensitive *Ezh2* variant. NMD inhibition increased and SRSF3 depletion decreased also the level of the intronless *Epop* mRNA encoding an ESC specific component of PRC2 ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}), suggesting that SRSF3 controls the expression of multiple components of the PRC2 complex. Similar to *Ezh2*, SRSF3 bound to and regulated the expression of a distinct NMD-sensitive variant of *Dnmt3a* (*Dnmt3a*-AltEx1) ([Figure 7G](#fig7){ref-type="fig"}). Interestingly, none of the investigated transcript variants contained premature termination codons (PTCs) generally associated with mRNAs targeted to NMD. To dissect if SRSF3 affected the production or stability of the NMD-sensitive transcript variants, we determined mRNA half-lives in Actinomycin D treated control and SRSF3-depleted pluripotent cells. *Myc* mRNA served as a control showing the expected half-life of 0.7 hr in ESCs ([@bib30]). The half-lives of the NMD-sensitive mRNAs were not significantly altered following SRSF3 depletion ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}), suggesting that SRSF3 regulates the generation of distinct mRNAs whose steady-state levels are maintained by NMD to balance production and turnover. Taken together, SRSF3 regulates the abundance of chromatin modifiers through binding to distinct NMD-sensitive transcript variants, SRSF3 depletion leading to global changes in the chromatin state of pluripotent stem cells.

Discussion {#s3}
==========

Here, we elucidate the essential role of SRSF3 in reprogramming and self-renewal by directly regulating key components of the NANOG-centred pluripotency circuitry ([Figure 8](#fig8){ref-type="fig"}). SRSF3 activity in coordinating the pluripotency gene expression program illustrates the central role of RBPs in modifying transcriptomes and regulating cell fate decisions.

![SRSF3 drives self-renewal by regulating RNAs encoding key pluripotency factors.\
SRSF3 directly regulates the core pluripotency network through its activities in mRNA export, alternative splicing and mRNA turnover. Through the control of RNAs encoding chromatin modifiers, transcription and RNA processing factors that are involved in the establishment and maintenance of pluripotency SRSF3 has a broad impact on the pluripotency gene expression program.](elife-37419-fig8){#fig8}

The importance of RNA processing as a means to regulate cell fate has only recently started emerging ([@bib11]; [@bib15]; [@bib34]). The functions of SR proteins, including SRSF3, have expanded from essential regulators of splicing to multifaceted mediators of RNA processing ([@bib57]). High-throughput technologies have allowed the cataloguing of SR protein targets, but the impact of SR protein RNA binding at the cellular level has remained largely elusive. Using our reprogrammable *Srsf3* knockout model that allowed a systematic investigation of SRSF3 activity in the generation and maintenance of iPSCs, we demonstrate that SRSF3 is required for both the proliferative phase and the later commitment to pluripotency. The proliferative response of the first wave of reprogramming was largely lost in SRSF3 deficient cells¸ in accordance with the previous RNAi screen ([@bib44]). However, SRSF3 depletion late during reprogramming also greatly reduced the generation of AP-positive pluripotent colonies. We show that SRSF3 controls the commitment to pluripotency directly by targeting key genes of the pluripotency network. Furthermore, overexpression of SRSF3 led to an increase in AP/SSEA1-positive cells, suggesting that SRSF3 could be used to enhance reprogramming efficiency.

Combination of iCLIP and RNA-seq revealed the significance of SRSF3-mediated RNA regulation for the establishment and maintenance of pluripotency. Remarkably, SRSF3 controlled the expression of the core pluripotency transcription factor NANOG by facilitating the nucleo-cytoplasmic export of *Nanog* mRNA. The nuclear sequestration of *Nanog* mRNA in SRSF3-deficient iPSCs led to greatly reduced NANOG protein levels. Consistent with this, the cellular phenotype of SRSF3-depleted pluripotent cells resembled that of *Nanog*-null cells ([@bib40]). We demonstrate that the function of SRSF3 in mRNA export is independent of splicing by showing that ectopically expressed intronless wild-type *Nanog* mRNA is efficiently exported. Mutation of SRSF3 consensus binding sites abolished SRSF3 binding to *Nanog* mRNA and resulted in the nuclear accumulation of the mRNA. In the absence of SRSF3-binding sites, the interaction between *Nanog* mRNA and the export factor NXF1 was lost, suggesting that SRSF3 is necessary and sufficient for the recruitment of NXF1 to *Nanog* mRNA. Interestingly, knockdown of THO complex components in ESCs resulted in mRNA export defects and loss of pluripotency ([@bib52]), suggesting that RBP-regulated export of distinct mRNAs may be broadly used to control gene expression in pluripotent cells.

SRSF3 directly regulated the splicing of multiple pre-mRNAs encoding established pluripotency factors, including other RNA regulators. In particular, SRSF3 bound to pre-mRNAs containing post-transcriptionally spliced detained introns ([@bib8]), one such pre-mRNA encoding the export receptor NXF1. We demonstrate that during reprogramming intron detention is dynamically regulated and may significantly modulate gene expression output in cell fate transitions. SRSF3 bound to and regulated the inclusion of DIs, as exemplified by *Nxf1* pre-mRNA. This extends the well-established role of SRSF3 in enhancing exon inclusion by binding to exonic splicing enhancers to intronic enhancer sequences. SRSF3 increased the production of an intron containing *Nxf1* transcript variant that encodes a short NXF1 isoform incapable of interacting with the nucleopore complex ([@bib37]). Thus, SRSF3 interacts with NXF1 at multiple levels, firstly by regulating *Nxf1* splicing and secondly, by functioning as an mRNA export adaptor of NXF1 at the protein level. This suggests that SRSF3 can influence mRNA export both by regulating NXF1 isoform expression and by directly mediating the export of distinct mRNAs such as *Nanog* in pluripotent cells. More broadly, our data identifies SRSF3 as a regulator of DI-containing pre-mRNAs encoding RBPs beyond *Nxf1,* suggesting that SRSF3 may influence RNA processing in pluripotent cells not only by regulating its direct RNA targets but also through the regulation of other RBPs ([Figure 8](#fig8){ref-type="fig"}).

Finally, SRSF3 depletion in pluripotent cells led to the downregulation of hundreds of mRNAs, many of which were direct SRSF3 targets. Interestingly, these mRNAs were also regulated at the level of NMD in pluripotent cells ([@bib23]). SRSF3 depletion affected explicitly the level of the NMD-sensitive transcript variants, suggesting a link between SRSF3 and mRNA surveillance pathway. One functional class of NMD-sensitive SRSF3 target mRNAs was chromatin modifiers involved in resetting the epigenome during reprogramming. As a functional output SRSF3 depletion led to a global decrease in repressive H3K27me3 histone marks that are deposited on the promoters of lineage regulators to suppress differentiation in pluripotent cells ([@bib56]). Surprisingly, the NMD-sensitive transcript variants did not contain PTCs that typically mark mRNAs for degradation. Recent studies have demonstrated that besides degrading aberrant PTC-containing mRNAs, NMD targets many seemingly 'normal' mRNAs ([@bib12]; [@bib24]) ([@bib23]). The mechanism by which normal mRNAs are targeted to NMD and the exact role of SRSF3 in the process will require further investigation.

Our results reveal the multifaceted role of SRSF3 in the control of gene expression programs during reprogramming and in self-renewing cells. The determination of SRSF3-mediated RNA processing in pluripotent stem cells not only highlights the significance of post-transcriptional gene regulation during self-renewal but also provides key mechanistic insights into SRSF3 functions during early development. *Srsf3*-null mice die before the blastocysts stage ([@bib28]), the source of ESCs in the mouse embryo. It is tempting to propose that the mechanisms identified here are applicable to early development. Perhaps *Srsf3*-null embryos cannot establish the pluripotency program due to premature activation of lineage-specific genes following reduced H3K27me3 levels. With drastically decreased production of NANOG protein, pluripotency would not develop in mice, ultimately causing early embryonic lethality ([@bib40]; [@bib49]). Furthermore, *Srsf3* is a proto-oncogene and its expression is frequently dysregulated in cancer cells ([@bib26]; [@bib32]). The mechanisms identified here may help elucidating the role of SRSF3 in malignant transformation as cancer (stem) cells share many features with self-renewing cells. In conclusion, our examination highlights the importance of RBPs in coordinating the gene expression program that is required to establish and maintain the pluripotent cell fate.

Materials and methods {#s4}
=====================

Mouse strains, primary cells and cell lines {#s4-1}
-------------------------------------------

*Srsf3* conditional allele was generated from *Srsf3*^tm1a(KOMP)Mbp^ knockout-first mice (Knock Out Mouse Project, KOMP, UC Davis Mouse Biology Program) via Flpe recombination. These mice were crossed with Tg(UBC-cre/ERT2)1Ejb/1J mice ([@bib46]) and further with m3-OKSM mice ([@bib1]). The resulting reprogrammable *Srsf3* knockout mouse strain (aka *Srsf3*-KO/OKSM) carried loxP sites flanking exons 2 and 3 of *Srsf3* gene, tamoxifen inducible CreERT2 under the control of *Ubc* promoter, a constitutively expressed CAG-*M3rtTA* reverse transactivator and a multicistronic *OKSM* cassette with a doxycycline (Dox) inducible promoter at the *Col1a1* locus. *Srsf3*-KO/OKSM mice were time mated and embryonic day 13.5 (E13.5) embryos were used for MEF isolation. MEFs isolated from m3-OKSM mice carrying an *Oct4*-GFP reporter ([@bib1]) were used to generate samples for RNA sequencing. All animal works were performed according to the Australian code for the care and use of animals for scientific purposes (NHMRC) and approved by the Monash University Animal Ethics Committee.

SRSF3-BAC ES cells and EGFP-NLS control cells were generated as previously by transfecting BAC-transgene encoding mouse *Srsf3* C-terminally tagged with EGFP or EGFP-NLS vector into mouse JM8A3.N1 ES cells ([@bib3]). The verified JM8A3.N1 ESC cells were obtained from the European Conditional Mouse Mutagenesis Program (EuCOMM) and were mycoplasma negative. Transfected cells were selected using geneticin, followed by enrichment for EGFP-positive cells by FASC. The mycoplasma-negative HEK293T cells were obtained from ATCC (CRL-3216).

Generation of expression constructs {#s4-2}
-----------------------------------

Lentiviral SRSF3 overexpression construct was generated by subcloning the cDNA encoding human *SRSF3* followed by *T2A* self-cleaving peptide and *EGFP* (*SRSF3-T2A-EGFP*) into the lentiviral vector pCCL. A vector carrying only EGFP was generated and used as a control. WT-*Nanog* and ΔSRSF3-*Nanog* cDNA sequences were ordered as synthetic gene fragments (Biomatik, Canada) and cloned under the EF1alpha promoter using NEBuilder HiFi DNA Assembly (New England Biolabs, MA, USA).

Reprogramming, ESC/iPSC culture and HEK293 cells {#s4-3}
------------------------------------------------

MEFs (passage 1--2) were seeded at the density of 2000 cells/cm^2^ on collagen coated dishes (High-Glucose DMEM, 15% FBS, 1 mM Sodium Pyruvate, 1 mM MEM non-essential amino acids, 10,000 U/ml penicillin/Streptomycin and 0.55 mM beta-mercaptoethanol) and cultured at 37°C and 5% CO~2~/5% O~2~. SRSF3 depletion was induced by 5 uM 4-hydroxy-tamoxifen (4-OHT). OKSM expression was induced by adding doxycycline (Dox, 2 ug/ml) for 13 days in iPSC culture medium (KnockOut DMEM, 15% FBS, 2 mM Glutamax, 1 mM MEM non-essential amino acids, 10,000 U/ml of penicillin/streptomycin, 1000 U/ml Leukemia Inhibitory Factor (LIF), 1 uM beta-mercaptoethanol), followed by 3 days of culture without Dox. For SRSF3 overexpression, reprogrammable MEFs were seeded as above and spin-infected with a lentiviral vector carrying *Srsf3*-T2A-EGFP or EGFP. Reprogramming was induced 24 hr post-infection with Dox. ESCs and iPSCs were maintained on irradiated MEF feeder cells in iPSC medium without penicillin/streptomycin. MEFs were depleted before iPSC collection for analysis. HEK293 cells were maintained in standard culture media (high-glucose DMEM, 10% FBS, 2 mM Glutamax, 10,000 U/ml of penicillin/streptomycin) at 37°C and 10% CO~2~.

AP staining and flow cytometry {#s4-4}
------------------------------

Reprogramming efficiency was determined by AP staining (Vector Red Alkaline Phosphatase Substrate Kit, Vector Laboratories, CA, USA) at days 13 and 16. For flow cytometric analysis of cell surface marker expression, the cells were stained with anti-Thy1.2--450 (eBioscience, CA, USA) and anti-SSEA1 (Cell Signalling Technology, MA, USA). Dead cells were excluded by staining with Propidium iodide (PI). Apoptosis was quantified by the proportion of AnnexinV-positive cells (FITC-AnnexinV, BD Pharmingen, NJ, USA), followed by flow cytometric analysis with the BD LSR II flow cytometer. Resulting data were analysed with the FlowJo software.

Teratoma formation assay {#s4-5}
------------------------

iPSC colonies were picked at day 16 and expanded for 4--5 passages. The iPSCs were MEF depleted and 1 × 10^6^ cells were injected subcutaneously into the dorsal flanks of immunodeficient 5- to 8-week-old female NOD-SCID mice. After 5 weeks, teratomas were harvested and fixed in 4% paraformaldehyde, embedded in paraffin, sectioned at 5 µm and stained with haematoxylin and eosin.

Nucleo-cytoplasmic fractionation {#s4-6}
--------------------------------

Nucleo-cytoplasmic fractionation of control and *Srsf3*-KO iPSCs induced with 4OHT for 24 hr was performed as described ([@bib41]) and RNA was isolated as below. The *Nanog* expression constructs were transfected into control or *Srsf3*-KO iPSCs using Lipofectamine 2000 (Thermo Fisher, MA, USA) and 24 hr later 4OHT was added. The fractionation was performed 24 hr post-induction.

RNA immunoprecipitation {#s4-7}
-----------------------

SRSF3-BAC ES cells and EGFP-NLS control cells were transfected with WT-*Nanog* or ΔSRSF3-*Nanog* vectors as above and 24 hr later the cells were MEF depleted and harvested. The cell pellets (1--5 × 10^6^ cells) were suspended into NET-2 buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.05% Nonidet P-40). The lysates were sonicated using Bioruptor (Diagenode, NJ, USA) and the supernatants used for RNA immunoprecipitation with anti-EGFP (Abcam, UK, ChIP grade) coupled Dynabeads Protein G (Thermo Fisher). RNA was isolated from the beads and input samples (5% of the lysate) as below for RT-qPCR. Similarly, the *Nanog* constructs were transfected into HEK293 cells using Lipofectamine 2000 and RNA immunoprecipitation was performed 24 hr later. To determine SRSF3 binding to WT-*Nanog* or ΔSRSF3-*Nanog* in HEK293 cells, the *Nanog* vectors were co-transfected with a vector carrying SRSF3-YFP or EGFP-NLS ([@bib3]) and RNA immunoprecipitations were performed as above. The RNA immunoprecipitations using anti-NXF1 antibody (Sigma Aldrich, MO, USA) and HEK293 cell lysates transfected with the WT-*Nanog* or ΔSRSF3-*Nanog* vectors were performed as described above.

Apoptosis inhibition, NMD inhibition and mRNA stability assays {#s4-8}
--------------------------------------------------------------

To inhibit apoptosis, control and *Srsf3*-KO iPSCs cells were treated with 25 uM QVD-OPh with or without 4OHT for 24--48 hr. The cells were MEF depleted and used for RNA or protein isolation or for FACS analysis. To inhibit NMD, control and *Srsf3*-KO iPSCs cells were treated with 4OHT for 24 hr, followed by 100 ug/ml CHX for two hours as in ([@bib23]) before MEF depletion and harvesting and RNA isolation. The RNA was used either for RNA-sequencing or for cDNA synthesis followed by qPCR as described below. For the mRNA stability assays, the 4OHT-induced control and *Srsf3*-KO iPSCs cells were treated with 10 uM actinomycin D for 0--24 hr. Cells were MEF depleted and harvested at the time points indicated in [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}, followed by RNA isolation and RT-qPCR as described below.

RNA extraction and quantitative real-time PCR {#s4-9}
---------------------------------------------

Total RNA was isolated using the TRI Reagent (Sigma-Aldrich) and subjected to DNaseI treatment. RNA was used for cDNA synthesis with SuperScript III Reverse Transcriptase (Thermo Fisher). Quantitative real-time PCR was performed in an AB 7500 real-time PCR system (Applied Biosystems, CA, USA) with Luminaris HiGreen qPCR Master Mix-low ROX (Thermo Fisher) and 0.3 uM primer mix ([Table 1](#table1){ref-type="table"}). The cycle threshold value (CT) was calculated for each sample and normalised to *Hprt*. The relative mRNA levels were calculated using ΔΔCT method.

10.7554/eLife.37419.027

###### Primers used in this study.

F = forward primer, R = reverse primer.

  Gene symbol                   Sequence                   
  ----------------------------- -------------------------- ------------------------
  *Srsf3*                       F                          TGAATTAGAACGGGCTTTTGG
  R                             TTCACCATTCGACAGTTCCAC      
  *Hprt*                        F                          TGTTGTTGGATATGC
  R                             TGCGCTCATCTTAGG            
  *Nanog*                       F                          ACCAAAGGATGAAGTGCAAGC
  R                             TGGATGCTGGGATACTCCACT      
  *Nanog TR*                    F                          GCAGTTTTTCATCCCGAGAAC
  R                             GAAGAGGCAGGTCTTCAGAGG      
  *Nanog FL*                    F                          TGACATGAGTGTGGGTCTTCC
  R                             GAAGAGGCAGGTCTTCAGAGG      
  *Pou5f1*                      F                          GAGGAAGCCGACAACAATGAG
  R                             5\'ATCTGCTGTAGGGAGGGCTTC   
  *Sox2*                        F                          GTAAGATGGCCCAGGAGAACC
  R                             ATAATCCGGGTGCTCCTTCAT      
  *Klf4*                        F                          GAAAAGAACAGCCACCCACAC
  R                             CCTGTCACACTTCTGGCACTG      
  *Zfp42*                       F                          AGATTAGCCCCGAGACTGAGG
  R                             AAGGGAACTCGCTTCCAGAAC      
  *Myc*                         F                          CTGTACCTCGTCCGATTCCAC
  R                             GGTTTGCCTCTTCTCCACAGA      
  *Nxf1*                        F                          TTCTGCCTGTCTGTTGTCTCC
  R                             CAGAACAGAAAAGGGGAGGTG      
  *Mbnl2*                       F                          AAAGCACTGAAGCGACCTCTC
  R                             AGAGCCTGCTGGTAGTGCAAG      
  *Ewsr1*                       F                          GCTTCAATAAGCCTGGTGGAC
  R                             TGCCAGATCATCCAGAGTCAC      
  *Fil1l1*                      F                          TCCAATAACTGTACCACCTCCA
  R                             CCATAGGGAACGCTCGTG         
  *Ezh2 Ex2-3*                  F                          AATCTGAGAAGGGACCGGTTT
  R                             ATGTGCACAGGCTGTATCCTC      
  *Ezh2 Ex19-20*                F                          GGGCTATCCAGACTGGTGAAG
  R                             CCTGAAGCTAAGGCAGCTGTT      
  *Epop*                        F                          CCGGCTGATGCTCTTTCTACT
  R                             CCGCTAAACTGACCCTCATTC      
  *Eed*                         F                          GGCAAACTGTATGTTTGGGATT
  R                             TCGCAGACAGCTATGAGGATG      
  *Wee1*                        F                          GAGCTGGTGAAGCATTCAGTG
  R                             CATCCGATCTGTGAAGAGTGC      
  *Dnmt3a Ex22-23*              F                          GGGGACCCCTACTACATCAGC
  R                             AGAGGCCTGGTTCTCTTCCAC      
  *Dnmt3a AltEx1*               F                          CCAGACGGGCAGCTATTTACA
  R                             AGAGGCCTGGTTCTCTTCCAC      
  *Nanog-WT and Nanog-ΔSRSF3*   F                          CAAGCCTCAGACAGTGGTTCA
  R                             ATGTCAGTGTGATGGCGAGG       

Western blotting {#s4-10}
----------------

For all Western blots, cells were lysed in RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% Nonidet P40, 0.5% Sodium deoxycholate, 0.1% SDS). NuPAGE 4--12% gradient Bis-Tris gel system (Thermo Fisher) was used in reducing conditions. The nitrocellulose membranes were probed with antibodies against SRSF3 (Sigma-Aldrich), NANOG (Abcam), H3K27me3 (Merck Millipore, Germany), Histone H3 (Abcam), γH2ax (Genetex, CA, USA) and beta-ACTIN (Abcam), followed by HRP-conjugated secondary antibodies (Biorad, CA, USA). The blots were developed using Amersham ECL Western Blotting Detection Reagents (GE Healthcare, UK) and visualised with the Biorad ChemiDoc MP Imaging System (UK). The band intensities were quantified with Fizi ([@bib47]).

iCLIP {#s4-11}
-----

SRSF3-BAC and EGFP-NLS control ESCs were UV crosslinked with 100mJ/cm^2^ and iCLIP was performed as in ([@bib22]). Protein G Dynabeads coupled with goat anti-GFP antibody (D. Drechsel, Max Planck Institute of Molecular Cell Biology and Genetics, Dresden) were used for immunopurification. Cross-linked, immunopurified RNA was digested to lengths of 60--150 nt, reverse-transcribed and subjected to sequencing on an Illumina HiSeq1500.

RNA-sequencing {#s4-12}
--------------

For RNA sequencing of reprogramming time course, SSEA1+ reprogramming intermediates at days 3--12 were enriched using AutoMACS Separator (Miltenyi Biotec, Germany) and anti-SSEA1 Microbeads (Miltenyi Biotec) according to the supplier's instructions. The enriched cells were labelled for FACS as in ([@bib42]). In short, the cells were labelled at approximately 30 × 10^6^ cells/ml at 4°C. Day 3 and day 6 cells were labelled in a primary labelling step with Anti-Mouse CD90.2 (Thy-1.2) eFluor 450 (eBioscience) and Anti-Human/Mouse SSEA-1 Biotin (eBioscience), followed by a secondary labelling step with APC Streptavidin (BD Pharmingen). Day 9 and day 12 cells were labelled in a primary labelling step with Anti-Mouse CD90.2 (Thy-1.2) eFluor 450 (eBioscience), Anti-Human/Mouse SSEA-1 Biotin (eBioscience) and Anti-Mouse CD117 (c-Kit) APC (eBioscience), followed by a secondary labelling step with Streptavidin PE (eBioscience). Dead cells were excluded by PI. iPSCs were FACS-sorted for Oct4-GFP expression. RNA was extracted from approximately 0.5 × 10^6^ FACS-sorted cells using the RNeasy Micro Kit (Qiagen, Germany) according to the manufacturer's recommendations. Sequencing libraries were generated using TruSeq RiboZero Kit and Illumina TruSeq protocol, high-throughput sequencing was carried out in duplicates on Illumina HiSeq1500 (100 nt paired end reads, 57--92M reads per sample).

For RNA-sequencing of control and SRSF3 *Srsf3*-KO iPSCs, the cells were induced with 4OHT for 24 hr, MEF depleted and RNA isolated as described above. The sequencing libraries were generated using Illumina TruSeq poly-A selection with strand-specific chemistry. Sequencing was carried out in duplicates on Illumina NextSeq (75nt paired end reads, \~65M reads per sample).

iCLIP and RNA sequencing data analysis {#s4-13}
--------------------------------------

The iCLIP data was analysed using iCount as described ([@bib5]; [@bib31]; [@bib41]; [@bib53]). In short, adapters and barcodes were removed from all reads before mapping to the mouse mm10 genome assembly. Uniquely mapping reads were kept to determine statistical significant crosslink sites. For this, iCLIP positions were randomised within co-transcribed regions and statistically significant binding sites (false discovery rate, FDR \< 0.05) were calculated. Three biological replicates for SRSF3-BAC and EGFP-NLS control ESCs were pooled for the analysis.

K-mer analysis was performed for motif search as described ([@bib31]; [@bib53]). One occurrence of k-mer (4-mers for noncoding RNAs and 5-mers for all RNAs) within the evaluated interval (−30,--5)(+5,+30) around the crosslink site was counted and weighted by 1.0. Reference data was generated 100 times by random shuffling of crosslink sites within corresponding genome segments and z-score was calculated relative to the randomized positions. The consensus binding motif was calculated from top 15 using MEME ([@bib7]). Gene Ontology analysis was performed using DAVID ([@bib19])

Paired-end RNA-seq reads aligned to the mm10 reference genome using STAR (v2.5.2) with default parameters ([@bib14]). The iPS-1 and iPS-2 control replicates were merged using samtools-merge (Samtools v1.2); producing a combined alignment for the control condition. Differential splicing analysis was done using MISO v0.5.4 (LINK1; in a relaxed configuration where filter_results = False) and the mm10 alternative event annotation (version 2; LINK2). For each AS event type, the treatment replicates were compared to the combined control (using miso_compare); this identified putative treatment-sensitive AS events. The results were then filtered using MISO's filter_events command (FILTERS: num-inc 1 = at least one inclusion read, num-exc 1 = at least one exclusion read, num-sum-inc-exc 10 = at least 10 reads of any kind in one of the samples' delta-psi 0.20 = minimum 0.2 delta PSI, bayes-factor 5 = bayes factor at least 5). Similarly, the paired-end MEF-to-iPSC time-course reads were aligned to the mm10 reference genome using STAR (v2.5.2). The differential splicing analysis was done as above.

Splice junctions from the MEF-to-iPSC time-course were reconstituted from the corresponding transcript annotations, flanked by 100 nt up- and downstream of each junction. The resulting alignments were used as input for JunctionSeq analysis ([@bib2]; [@bib18]), which is based on the DEX-seq model but has been reported to detect readily novel splice junctions and intron retention. Briefly, exon coordinates from transcript models with a Transcript Support Level of 1 (the most stringent) were extracted and used as input for QoRTS ([@bib17]), together with the alignments from the time-course RNA-seq data. The capability of QoRTS to call novel splice junctions from the data was enabled. The output from QoRTS, a flat exon/junction annotation file, was used together with the alignment data as input for the JunctionSeq software to detect differential exon/junction usage between time-points. Each time-point was contrasted against the original MEF cells (day-0) in one JunctionSeq run. In another run, each time-point was contrasted to the previous time-point. In a third run, all time-points were considered together in the one linear model to test for any effect at all of time-point on exon/junction usage. Log~2~-fold changes reported are all variance-stabilised transformation of the original log~2~ fold-changes in expression estimates. In each of the pairwise contrast between timepoints, exonic/junction, features with a FDR \< 0.05 were classed as \'regulated\', while others were classed either as unregulated (FDR \> 0.05), or \'untestable\' (too few reads observed in both time points), by JunctionSeq.

Data for SRSF3 iCLIP was filtered for sites that also appeared in the GFP iCLIP control, then converted to bed format. This data was then merged with the exon/junction feature annotations from QoRTS (including de novo junction calls) using BedTools. Detained intron data ([@bib8]) was similarly merged with the QoRTS annotation. For k-means clustering of time-point data, a minimum autocorrelation filter (correlation between consecutive time-points) was set at 0.1, and maximum and minimum log~2~ fold changes of 8.5 and 0.5, respectively, were also applied. The number of clusters was set to 20. The interaction analysis used for [Figure 3](#fig3){ref-type="fig"} was performed with STRING ([@bib50]).

Statistical information {#s4-14}
-----------------------

The statistical analysis was conducted using Graph Pad Prism 7 or R. Unpaired Student's t-test was used when two conditions were compared, One-way ANOVA for comparison of three or more experimental conditions and two-way ANOVA when comparisons included multiple variables (such as treatment and time). The number of biological replicates, details of the statistical methods used and how statistical significance was defined is indicated in each figure legend.

Data availability {#s4-15}
-----------------

RNA-sequencing data for the reprogramming time-course is deposited in GEO Accession Number GSE101905 and RNA-sequencing data for *Srsf3*-KO and control iPSCs in GEO Accession Number is GSE113794. iCLIP data is available in the public version of iCount (<http://icount.biolab.si>) and as source data to [Figure 3](#fig3){ref-type="fig"}.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"SRSF3 promotes pluripotency through Nanog mRNA export and coordination of the pluripotency gene expression program\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom, Juan Valcárcel is a member of our Board of Reviewing Editors and the evaluation has been overseen by a Reviewing Editor and a Senior Editor.

The editors and referees agreed that there was too much further work needed to ask for a revised version at this point (see joint report below) and we are therefore returning your manuscript to you in case you wish to submit elsewhere. However, if you are willing and able to carry out the additional experiments and analysis requested, we would welcome the submission of a revised paper at a later date. This would be treated as a new submission with no guarantees of acceptance.

Summary:

Ratnadiwakara et al. further explore the role of the SR protein SRSF3 in reprogramming using a tamoxifen inducible Srsf3 mouse KO model in conjunction with a system for Dox induced expression of OKSM factors to reprogram MEFs to iPSCs. The study confirms the prior report by Ohta et al. showing that Srsf3 is induced during reprogramming and that depletion or ablation of Srsf3 reduces reprogramming efficiency as well as a loss of established pluripotency markers in iPSCs and loss of iPSC colony formation. The investigators note that there is a substantial reduction in protein levels of the pluripotency gene Nanog, but not mRNA in iPSCs following inducible Srsf3 KO. Follow up experiments supported the concept that Srsf3 promotes nuclear export of Nanog mRNA. Subsequent iCLIP experiments identify Nanog as a direct target of Srsf3 with binding sites in the first and last coding exon. A model is proposed where Srsf3 ablation leads to a loss of Nanog export. The iCLIP results also reveal other Srsf3 associated transcripts encoding pluripotency markers as well of regulators of chromatin state and other RNA binding proteins. Further studies explore the role of Srsf3 in regulating alternative splicing and stability of several targets, including the export receptor Nxf1, which had previously been shown to associate with Srsf3 and play a role in export. How this might be mechanistically linked to the effects on Nanog localization is not clear. Subsequent studies use RNA-Seq to identify changes in gene expression across the reprogramming time course and identify enrichment of Srsf3 binding features in or near several regulated exons and introns. mRNA-Seq was not carried out after Srsf3 depletion -- which would have allowed more direct identification of Srsf3-regulated alternative splicing events. Since Srsf3 levels increase during reprogramming, it is reasonable to assume that a fraction of regulated events will be influenced by Srsf3. RNA features regulated during reprogramming and with associated Srsf3 CLIP tags were therefore identified (\"SARFs\"). A large fraction of SARFs showed intron binding -- rather than the exon binding characteristic of splicing enhancement by Srsf3 -- and many of the intron binding events overlapped with \"detained introns\" identified by Boutz and colleagues. The remaining experimental data looked into some examples of potential Srsf3 regulated splicing events with possible connections to the observed phenotype.

The manuscript is clearly written and presented, and the initial experiments setting up the iPS system with Srsf3 KO carefully conducted. The results are of interest because they emphasize the role of coordinated, multilayer post-transcriptional mechanisms of regulation in cellular pluripotency. The report confirms the important role of Srsf3 in pluripotency and development and has the potential to further inform our understanding of the mechanisms by identifying a number of different processes and targets that may be directly regulated by Srsf3. However, given that previous publications (adequately referenced by the authors) have already reported a role for SRSF3 in cell reprogramming (including effects on alternative splicing and nucleo-cytoplasmic transport of genes relevant for pluripotency, including Nanog), for publication in *eLife* the authors should make additional efforts to a) better document many of the experimental results, and b) consolidate the more novel aspects of their mechanistic findings (e.g. the role of SRSF3 on Nanog mRNA export).

Essential revisions:

1\) Function of SRSF3 in mRNA export (Figure 4): further work is required to rigorously prove that SRSF3 binding is essential for Nanog mRNA export, that this is the main post-transcriptional mechanism of regulation of this transcript and that it has an impact on cell reprogramming. Nucleo-cytoplasmic distribution analysis of Nanog transcripts (Figure 4C) is not convincing, including the surprising equal partition of *Hprt* mRNAs, the apparent variability in the fraction of Nanog nuclear transcripts under normal conditions (0.4 in Figure 4C, 1.0 in Figure 4F), the relatively small (2-3 fold) and equal amount of nuclear and cytoplasmic mRNA in KO cells (which hardly seems to qualify as an export block) and, most importantly, the absence of standard marker analysis of the nucleus/cytoplasmic fractionation.

Furthermore, the experiments in Figure 4D and 4E are difficult to interpret as they are not explained in the text, legends, or Materials and methods section. Presumably these are overexpressed cDNAs? Were there any introns in the plasmid? If not, there might be concerns that the Srsf3-dependent export might be related to this artificial setting? Quantification of the total RNA levels of WT and ΔSRSF3 mRNAs should be shown, as well as statistical significance of differences in Figure 4E.

Given that Muller-McNicoll et al. already reported a role for SRSF3 in *Nanog* mRNA N/C transport, further demonstration that this is a limiting step in reprogramming would be expected. For example, is there evidence that the reduction in NANOG levels caused by the defect in transport is sufficient to compromise reprogramming (e.g. are ΔSRSF3 *Nanog* transcripts, expressed at levels comparable to endogenous *Nanog*, insufficient to mediate reprogramming)?

2\) Documenting splicing changes associated with SRSF3 (Figure 5). The methods for quantitative analysis of splicing from RNA-Seq data and the subsequent follow up by qRT-PCR data in most cases did not allow assessment of the true degree of splicing change in KO cells or of the likelihood that identified events were truly connected to the phenotype. Specifically, none of the changes in splicing were expressed as changes in \"percent spliced in\" (PSI) or \"percent intron retention\" (PIR). Instead the focus was on statistically significant relative fold-changes of individual spliced junctions. Ideally, all the examples of regulated events should include quantitative information about the PSI changes observed.

Indeed from the genome browser views shown (Figure 5E,G and Figure 5---figure supplement 1E-H) only the increased Mbnl2 e6 inclusion (Figure 5E) was readily apparent by manual inspection. Even for this case, it would be helpful if the PSI values from RNA-Seq and from an RT-PCR spanning both introns flanking alt exon 6 (i.e. to look directly at inclusion versus skipping) were shown because the level of exon 6 in MEFs appears negligible, and hence it is not clear if a 3-fold increase in exon 6 splicing is quantitatively meaningful. It is also noted that the level of exon 6 inclusion in control cells does not change during the period of Srsf3 upregulation, calling into question the model where it promotes exon skipping. Figure 5E appears to show a substantial increase in PSI of Mbnl2 exon 6 between MEFs and iPSCs (judged from the relative height of the exon peaks -- junction reads are not shown, Figure 5E and Figure 5---figure supplement 1F), as well as an increase in retention of introns 5 and 7. Yet in the time course in Panel F, the \"exon inclusion\" is quantitated by normalizing the exon 6-7 amplicon against *Hprt* and shows no change between day 1 and 16 (both are \~1.0). Perhaps this is because the qRT-PCR primers detect changes in both exon 6 PSI and expression level changes of Mbnl2, so that increased PSI is balanced by decreased overall Mbnl2 expression? If qRT-PCR is used to monitor relative changes in particular isoforms/alternative junctions, there should always be a separate primer pair across a constitutive junction in the same gene e.g. exon 7-8 in this case. A reciprocal primer pair should also ideally be used to assess the alternative \"feature\" -- in this case Mbnl2 exon 6 skipping. Alternatively, RT-PCR using a single pair of primers in exons 5 and 7 could be used to give a direct read-out of PSI.

Similarly, the intron retention event in Nxf1 appears relatively low without an apparent difference in MEFs vs. iPSCs. This event does not appear in EST databases, raising the question as to whether the intron reads seen in the RNA-Seq represent unspliced introns that are nonetheless removed prior to export. While there is certainly a substantial reduction in intron 10 retention in response to Srsf3 KO (Figure 5H), intron retention appears to be a relatively minor pathway that does not appear to be strongly regulated during reprogramming (Figure 5---figure supplement E). Thus, the possible effect of Srsf3 to produce a possible truncated protein remains speculative and there is not sufficient evidence for \"SRSF3 binding led to increased intron inclusion and production of a transcript variant encoding a short isoform of NXF1.\"

3\) RNA-seq analyses. Unfortunately, the authors did not carry out a corresponding RNA-Seq analysis of gene expression and splicing in Srsf3 KO cells compared to controls at a relevant time point (e.g. day 16) to more directly validate the functionality of the Srsf3 binding targets by iCLIP. This is a necessary experiment and would be particularly valuable given that the authors did not have immunoprecipitation or input controls for the iCLIP which has been shown in several studies to be important to identify bona fide direct targets.

It would also be useful to summarize the types of RNA feature that are detected by JunctionSeq (it does not appear to consider the \"classical\" alternative splicing event types involving reciprocally changing features (cassette exon, retained intron etc), but rather individual splice junctions). It might be worth considering using one of the analysis pipelines that analyses \"events\" and provides a deltaPSI output (e.g. MISO, rMATS, MAJIQ...).

4\) Data supporting a role for SRSF3 in regulating mRNA stability or other events (Figure 6). These data are either counterintuitive or are difficult to understand at the gene level. There are no experiments using standard mRNA stability assays (such as changes in half life after actinomycin D) and it is not clear in each of the cases shown how NMD would explain the differences in mRNA levels. The authors would need to show clearly how premature termination codons (PTCs) are being introduced in order to understand how NMD is involved. For *Ezh2* and *Dnmt3a* do they propose that an alteration in splicing is rendering the transcripts subject to NMD? If NMD is being invoked to explain the reduction in total mRNA in 6A, then it is not clear why both Ex 2-3 and Ex 19-20 primers would not show reduced levels in KO. In the case of *Epop*, there is no indication as to how the authors think NMD would account for the reduction in mRNA levels from this intronless gene with no PTC. Did the observed overlap of SRSF3 CLIP tags with detained intron events (Figure 5) and NMD-associated events (Figure 6) represent statistically significant enrichments?

10.7554/eLife.37419.041

Author response

> Essential revisions:
>
> 1\) Function of SRSF3 in mRNA export (Figure 4): further work is required to rigorously prove that SRSF3 binding is essential for Nanog mRNA export, that this is the main post-transcriptional mechanism of regulation of this transcript and that it has an impact on cell reprogramming. Nucleo-cytoplasmic distribution analysis of Nanog transcripts (Figure 4C) is not convincing, including the surprising equal partition of Hprt mRNAs, the apparent variability in the fraction of Nanog nuclear transcripts under normal conditions (0.4 in Figure 4C, 1.0 in Figure 4F), the relatively small (2-3 fold) and equal amount of nuclear and cytoplasmic mRNA in KO cells (which hardly seems to qualify as an export block) and, most importantly, the absence of standard marker analysis of the nucleus/cytoplasmic fractionation.
>
> Furthermore, the experiments in Figure 4D and 4E are difficult to interpret as they are not explained in the text, legends, or Materials and methods section. Presumably these are overexpressed cDNAs? Were there any introns in the plasmid? If not, there might be concerns that the Srsf3-dependent export might be related to this artificial setting? Quantification of the total RNA levels of WT and ΔSRSF3 mRNAs should be shown, as well as statistical significance of differences in Figure 4E.
>
> Given that Muller-McNicoll et al. already reported a role for SRSF3 in Nanog mRNA N/C transport, further demonstration that this is a limiting step in reprogramming would be expected. For example, is there evidence that the reduction in NANOG levels caused by the defect in transport is sufficient to compromise reprogramming (e.g. are ΔSRSF3 Nanog transcripts, expressed at levels comparable to endogenous Nanog, insufficient to mediate reprogramming)?

First, we would like to clarify the experimental details of the *Nanog* mRNA export experiments that were carefully designed to control for any artefacts. These clarifications are also provided in the amended Results section and/or Materials and methods section of the manuscript. In experiments presented in Figure 4D-G, a WT-*Nanog* overexpression construct was used as a control to assure that the lack of introns or the level of expression did not have an impact on the interpretation of the results. Furthermore, primers specific for the overexpressed constructs were used and the same primers were used to quantify both WT-*Nanog* and ΔSRSF3-*Nanog* levels. As shown in the new supporting figure, the WT-*Nanog* and ΔSRSF3-*Nanog* mRNAs were expressed at equal levels that were comparable to the endogenous *Nanog* mRNA level (Figure 4---figure supplement 1). The WT-*Nanog* cDNA overexpressed in control pluripotent cells was exported similar to the endogenous *Nanog* mRNA (Figure 4C, F). In SRSF3-KO cells, endogenous *Nanog*, overexpressed WT-*Nanog* and ΔSRSF3-*Nanog* mRNAs were all retained in the nucleus. We also transfected the WT-*Nanog* and ΔSRSF3-*Nanog* constructs into HEK293 cells that do not express endogenous *Nanog* but do express SRSF3 and NXF1 and show that similar to pluripotent cells WT-*Nanog* mRNA is exported while the ΔSRSF3-*Nanog* is retained. We further show that NXF1 is not able to bind to *Nanog* mRNA lacking SRSF3 binding sites but binds to WT-*Nanog*. Importantly, the use of the cDNA constructs allowed us to show that the function of SRSF3 in mRNA export can be separated from its activity in splicing.

There are conflicting reports on the effect of NANOG on reprogramming outcome and its role during reprogramming, suggesting that the exact timing of NANOG overexpression is likely critical. As determining the time window for NANOG overexpression in reprogramming is beyond the scope of this manuscript, we did not perform the experiment overexpressing ΔSRSF3-*Nanog* during reprogramming. We would like to note that similar to the role of SRSF3 in mRNA export, the depletion of the THO export complex involved in the export of a different set of mRNAs in pluripotent cells and during reprogramming, is sufficient to induce differentiation and inhibit reprogramming. This suggests that mRNA export is broadly used as a post-transcriptional mechanism to regulate pluripotency. We have referenced the THO paper in the manuscript.

Specific questions regarding Figure 4C and F nucleo-cytoplasmic distribution analysis: The values in 4C have been normalised to Ctrl (=1), so they are relative values. Similarly, in 4F the values have been normalised to Ctrl. Thus, values in Figures 4C and 4F are not directly comparable. This also means that *Hprt* levels are not equal in the nucleus and cytoplasm. Of note, at least for *Actb* mRNA in Mueller-McNicoll et al., 2017, the mature mRNA levels are equal in the nucleus and cytoplasm (Figure 4---figure supplement 1B of the paper). We have included the standard marker analysis for nucleo-cytoplasmic fractionation in Figure 4---figure supplement 1. We have included more detail in the text and figure legends to clarify the experimental design and data analysis. We have added the total mRNA quantifications in Figure 4---figure supplement 1.

> 2\) Documenting splicing changes associated with SRSF3 (Figure 5). The methods for quantitative analysis of splicing from RNA-Seq data and the subsequent follow up by qRT-PCR data in most cases did not allow assessment of the true degree of splicing change in KO cells or of the likelihood that identified events were truly connected to the phenotype. Specifically, none of the changes in splicing were expressed as changes in \"percent spliced in\" (PSI) or \"percent intron retention\" (PIR). Instead the focus was on statistically significant relative fold-changes of individual spliced junctions. Ideally, all the examples of regulated events should include quantitative information about the PSI changes observed.
>
> Indeed from the genome browser views shown (Figure 5E,G and Figure 5---figure supplement 1E-H) only the increased Mbnl2 e6 inclusion (Figure 5E) was readily apparent by manual inspection. Even for this case, it would be helpful if the PSI values from RNA-Seq and from an RT-PCR spanning both introns flanking alt exon 6 (i.e. to look directly at inclusion versus skipping) were shown because the level of exon 6 in MEFs appears negligible, and hence it is not clear if a 3-fold increase in exon 6 splicing is quantitatively meaningful. It is also noted that the level of exon 6 inclusion in control cells does not change during the period of Srsf3 upregulation, calling into question the model where it promotes exon skipping. Figure 5E appears to show a substantial increase in PSI of Mbnl2 exon 6 between MEFs and iPSCs (judged from the relative height of the exon peaks -- junction reads are not shown, Figure 5E and Figure 5---figure supplement 1F), as well as an increase in retention of introns 5 and 7. Yet in the time course in Panel F, the \"exon inclusion\" is quantitated by normalizing the exon 6-7 amplicon against Hprt and shows no change between day 1 and 16 (both are \~1.0). Perhaps this is because the qRT-PCR primers detect changes in both exon 6 PSI and expression level changes of Mbnl2, so that increased PSI is balanced by decreased overall Mbnl2 expression? If qRT-PCR is used to monitor relative changes in particular isoforms/alternative junctions, there should always be a separate primer pair across a constitutive junction in the same gene e.g. exon 7-8 in this case. A reciprocal primer pair should also ideally be used to assess the alternative \"feature\" -- in this case Mbnl2 exon 6 skipping. Alternatively, RT-PCR using a single pair of primers in exons 5 and 7 could be used to give a direct read-out of PSI.
>
> Similarly, the intron retention event in Nxf1 appears relatively low without an apparent difference in MEFs vs. iPSCs. This event does not appear in EST databases, raising the question as to whether the intron reads seen in the RNA-Seq represent unspliced introns that are nonetheless removed prior to export. While there is certainly a substantial reduction in intron 10 retention in response to Srsf3 KO (Figure 5H), intron retention appears to be a relatively minor pathway that does not appear to be strongly regulated during reprogramming (Figure 5---figure supplement 1E). Thus, the possible effect of Srsf3 to produce a possible truncated protein remains speculative and there is not sufficient evidence for \"SRSF3 binding led to increased intron inclusion and production of a transcript variant encoding a short isoform of NXF1.\"

To quantify splicing changes following SRSF3 depletion, we have used MISO and expressed the splicing changes as delta-PSI or PIR. We have used PSI or PIR values in all figures when possible. For the qPCR analysis of *Nxf1* intron retention, we expressed the data as% -retained (retained/total) which takes into account any changes in expression. We have used both MISO and JunctionSeq analysis in the context of the reprogramming time course (Figure 5 and Figure 6), as well as compared the two. To further consolidate the data, we have now focused on *Nxf1* splicing regulation and provide other regulated events as further examples of the dynamic SRSF3 mediated splicing during reprogramming. We have included in the Figure 6---figure supplement 1 data on previously identified transcripts with intron detention and show that we can detect these events, and in fact, *Clk1* and *Mdm4* that were previously investigated by Boutz et al. are regulated during reprogramming. This provides further support for the dynamic changes in intron detention during reprogramming, and the involvement of SRSF3 in the splicing of detained introns and exons flanking them.

Specific queries regarding Figure 5 (current Figures 5 and 6): Although PIR or PSI differences between MEFs and iPSC were not large, there was in each case a significant change in the course of reprogramming (for example, *Nxf1* intron retention increased from PIR 0.1 to 0.4 by day 12 which exceeds the commonly used significance criterion of 0.2). Furthermore, by only comparing MEFs to iPSC many important regulatory events are clearly missed and RNA processing changes during cell transitions need to be characterised throughout the process. There are a number of published papers (that we cite) on the *Nxf1* intron retention event and it is annotated in multiple genome databases so it is surprising if it does not appear in EST databases. It is hard to define what level of splicing is biologically meaningful and any cut-off is arbitrary. We feel that the strong loss-of-pluripotency phenotype is the best evidence for the biological significance of SRSF3 mediated splicing regulation during reprogramming and in pluripotent cells.

> 3\) RNA-seq analyses. Unfortunately, the authors did not carry out a corresponding RNA-Seq analysis of gene expression and splicing in Srsf3 KO cells compared to controls at a relevant time point (e.g. day 16) to more directly validate the functionality of the Srsf3 binding targets by iCLIP. This is a necessary experiment and would be particularly valuable given that the authors did not have immunoprecipitation or input controls for the iCLIP which has been shown in several studies to be important to identify bona fide direct targets.
>
> It would also be useful to summarize the types of RNA feature that are detected by JunctionSeq (it does not appear to consider the \"classical\" alternative splicing event types involving reciprocally changing features (cassette exon, retained intron etc.), but rather individual splice junctions). It might be worth considering using one of the analysis pipelines that analyses \"events\" and provides a deltaPSI output (e.g. MISO, rMATS, MAJIQ...).

We have now included the RNA-sequencing of SRSF3 deficient cells in the manuscript. We analysed the data using MISO and show that substantial splicing changes take place following SRSF3 depletion. We show the different types of events that are affected, provide examples of regulated events as well as a global map of SRSF3 binding sites over skipped exons affected by SRSF3 ablation. We focused our analysis on skipped exons because this is the largest group annotated and assessed by MISO and thus provided a sufficient number of data points for reliable analysis. The 'SRSF3 RNA-map' is first of its kind as previous SRSF3 CLIP-seq or RNA-seq studies have not mapped the binding sites to regulated exons.

We have now analysed the reprogramming time course RNA-seq data using MISO and JunctionSeq. We demonstrate that AS is affected across event types during reprogramming. We have included the proportions of the different types of AS events during the reprogramming time course. We originally chose to use JunctionSeq because it allowed an unbiased assessment of both annotated and novel RNA processing changes. Our focus was to determine the localisation of SRSF3 binding sites relative to splice junctions that change during reprogramming and therefore JunctionSeq was a good alternative. This analysis captured the previously reported cumulative increase in alternative splice site usage from MEFs to iPSCs (Ohta et al., 2013 and Cieply et al., 2016) and readily captured RNA processing changes across expression levels and independent of gene expression changes (Figure 6---figure supplement 1). The re-analysis using MISO did not change our interpretations. Importantly, it further confirmed that most splicing changes take place at day 3 and iPSC, and that the comparison of iPSCs to MEFs represents a cumulative increase in AS, the transition from day 12 to iPSC contributing most events.

> 4\) Data supporting a role for SRSF3 in regulating mRNA stability or other events (Figure 6). These data are either counterintuitive or are difficult to understand at the gene level. There are no experiments using standard mRNA stability assays (such as changes in half life after actinomycin D) and it is not clear in each of the cases shown how NMD would explain the differences in mRNA levels. The authors would need to show clearly how premature termination codons (PTCs) are being introduced in order to understand how NMD is involved. For Ezh2 and Dnmt3a do they propose that an alteration in splicing is rendering the transcripts subject to NMD? If NMD is being invoked to explain the reduction in total mRNA in 6A, then it is not clear why both Ex 2-3 and Ex 19-20 primers would not show reduced levels in KO. In the case of Epop, there is no indication as to how the authors think NMD would account for the reduction in mRNA levels from this intronless gene with no PTC. Did the observed overlap of SRSF3 CLIP tags with detained intron events (Figure 5) and NMD-associated events (Figure 6) represent statistically significant enrichments?

We have now clarified this section. We have included the analysis of differential gene expression in SRSF3 depleted cells as well as compared DEGs to the data from Hurt et al., 2013. We have re-worded our conclusions based on the current Figure 7 to state that SRSF3 is involved in controlling the steady-state levels of distinct mRNAs regulated by NMD in pluripotent cells. Our data and the data by Hurt et al. show that in many cases only one mRNA (called isoform in Hurt et al.) is affected by NMD inhibition, suggesting that transcripts produced from a single gene can be differentially regulated. It is important to note that these mRNAs (isoforms) do not necessarily contain PTCs. Multiple recent studies (for instance, Imamachi et al., 2017, Colombo et al., 2017, Hurt et al., 2013 and Zund et al.) demonstrate that besides degrading aberrant mRNAs that harbor PTCs, NMD also targets many seemingly \"normal\" mRNAs that encode full-length proteins. Further studies are required to fully define how the NMD machinery recognises these mRNAs. We show that SRSF3 specifically binds to and regulates the abundance of NMD-sensitive mRNAs (isoforms).

Specific queries regarding Figure 7: We have now determined the half-lives of the mRNAs as in Ke et al., 2016 and added n values or statistics where relevant.

[^1]: Australian Regenerative Medicine Institute, Monash University, Clayton, Australia.
